Literature DB >> 9506605

Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus.

S Lehto1, L Niskanen, T Rönnemaa, M Laakso.   

Abstract

BACKGROUND AND
PURPOSE: Patients with non-insulin-dependent diabetes mellitus (NIDDM) are at increased risk for stroke. Hyperuricemia is a common finding in NIDDM, but its significance as an independent risk factor for cardiovascular disease has remained uncertain. Therefore, we investigated serum urate as a predictor of stroke in NIDDM patients free of clinical nephropathy (ie, with a serum creatinine level of < or = 120 micromol/L).
METHODS: In this population-based study, cardiovascular risk factors were determined in 1017 patients (551 men and 466 women) with NIDDM, aged 45 to 64 years at baseline. The patients were followed up for 7 years with respect to stroke events.
RESULTS: During the follow-up period, 31 NIDDM patients (12 men [2.2%] and 19 women [4.1%]) died from stroke and 114 NIDDM patients (55 men [10.0%] and 59 women [12.7%]) had a fatal or nonfatal stroke. The incidence of stroke increased significantly by quartiles of serum uric acid levels (P<.001). High uric acid level (above the median value of > 295 micromol/L) was significantly associated with the risk of fatal and nonfatal stroke by Cox regression analysis (hazard ratio, 1.93 [1.30 to 2.86]; P=.001). This association remained statistically significant even after adjustment for all cardiovascular risk factors (hazard ratio, 1.91 [1.24 to 2.94]; P=.003).
CONCLUSIONS: Our results indicate that hyperuricemia is a strong predictor of stroke events in middle-aged patients with NIDDM independently of other cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506605     DOI: 10.1161/01.str.29.3.635

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  90 in total

1.  Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged.

Authors:  K Sakata; T Hashimoto; H Ueshima; A Okayama
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 2.  Serum uric acid as a cardiovascular risk factor for heart disease.

Authors:  M H Alderman
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 3.  Hyperuricemia and renal function.

Authors:  L M Ruilope; J Garcia-Puig
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

4.  Serum uric acid and cardiovascular disease.

Authors:  Adriana Iliesiu; Alexandru Campeanu; Dinu Dusceac
Journal:  Maedica (Buchar)       Date:  2010-07

Review 5.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 6.  Recent advances in the epidemiology of gout.

Authors:  Kenneth G Saag; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

7.  Study of epidemiological aspects of hyperuricemia in Poland.

Authors:  Katarzyna Kostka-Jeziorny; Krystyna Widecka; Andrzej Tykarski
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

Review 8.  Higher Serum Uric Acid May Contribute to Cerebral Infarction in Patients with Type 2 Diabetes Mellitus: a Meta-Analysis.

Authors:  Lei Du; Jianhua Ma; Xiaoning Zhang
Journal:  J Mol Neurosci       Date:  2016-10-01       Impact factor: 3.444

9.  Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly.

Authors:  A Mazza; A C Pessina; A Pavei; R Scarpa; V Tikhonoff; E Casiglia
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 10.  Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?

Authors:  Zohreh Soltani; Kashaf Rasheed; Daniel R Kapusta; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.